1. Home
  2. RYTM

as 09-05-2025 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Founded: 2008 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 5.9B IPO Year: 2017
Target Price: $101.92 AVG Volume (30 days): 550.8K
Analyst Decision: Strong Buy Number of Analysts: 13
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.02 EPS Growth: N/A
52 Week Low/High: $45.91 - $106.52 Next Earning Date: 11-04-2025
Revenue: $156,287,000 Revenue Growth: 53.55%
Revenue Growth (this year): 44.69% Revenue Growth (next year): 63.53%

RYTM Daily Stock ML Predictions

Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Shulman Joseph RYTM Chief Technical Officer Sep 2 '25 Sell $105.30 16,781 $1,767,005.74 8,509
Shulman Joseph RYTM Chief Technical Officer Aug 21 '25 Sell $100.07 4,188 $419,090.65 8,509
Smith Hunter C RYTM Chief Financial Officer Aug 13 '25 Sell $96.00 3,477 $333,792.00 116,915
Smith Hunter C RYTM Chief Financial Officer Aug 12 '25 Sell $96.33 24,611 $2,370,831.77 116,915
German Christopher Paul RYTM Corporate Controller & CAO Aug 12 '25 Sell $95.00 1,500 $142,500.00 922
Shulman Joseph RYTM Chief Technical Officer Aug 11 '25 Sell $90.08 3,984 $358,891.47 8,509

Share on Social Networks: